Latest Daily Edition Stories
Sangamo’s Study Of Genome Editing In Rare Disease Is First To Target Effects On Humans
Biotech company Sangamo Therapeutics, headquartered in Richmond, Calif., is expected to release preliminary results next month in the first clinical trial using genome editing to treat real patients. In other health research news: a banking and regulatory adviser works to get private investors to bankroll a cure for blindness; the “perfect lab animal”? worms; and drug comparative effectiveness research.
Black Men More Likely To Have Certain Health Tests If Discussed With A Black Male Doctor: Study
A survey of 702 black men in Oakland, Calif., indicates that the lack of black physicians may be a factor in the health care disparity for black men. In other news: some docs have a hard time talking to patients about the downsides of cancer screenings; and the growing number of practicing osteopaths.
First Generic Version Of EpiPen Injector Approved By FDA And Could Lower Cost Of Drug
Teva gets approval from the Food and Drug Administration to sell its version of the epinephrine auto-injector, but hasn’t yet revealed its pricing. Mylan, the manufacturer of the brand-name EpiPen, has faced public criticism and congressional investigations for raising the price of its lifesaving drug 450 percent since 2004.
If Doctors Use Your Data To Develop Treatments, Do They Need To Tell You?
Ethicists, patients, doctors and courts are wrestling with that question as efforts grow to expand care through better data and technology. Also, Stat offers a guide to CRISPR, and Madrigal Pharmaceuticals says one of its drugs has shown progress treating fatty liver disease.
Doctors Are Prescribing Fewer Opioids, Says AMA
The number of opioid prescriptions in the U.S. dropped 22 percent between 2013 and 2017, leading to an estimated 55 million fewer scripts, according to the doctors’ group. These numbers are part of the American Medical Association’s argument against proposed federal clinical practice legislation. Also in the news, an exposé on the marketing techniques used by some corners of big pharma regarding these medicines. Meanwhile, updates on California’s experiment in distributing fentanyl tests.
When CEO Pay Is Corrected, The Number Can Be Dramatic
In other health industry news, Allergan announced it will sell its women’s health, infectious-disease units, as well as a voluntary recall of nearly 170,000 birth control packs because of a packaging error that could lead to unintended pregnancy.
The prominent cancer organization changes its guidelines to encourage Americans to undergo colorectal cancer screening starting at 45 instead of waiting until 50. Since 1994, there has been a 51 percent increase in the rate of the disease among those younger than 50, and the death rate also has started to rise.
Medicine Is Turning To Artificial Intelligence To Help Patients
Machines — programmed with experiences from at times millions of humans — are providing doctors new insights into identifying and treating disease and predicting health problems.
Health And Wellness Roundup: Hope For Migraine Sufferers; And What About That Numb Thumb?
Media outlets also report on California STD rates, the changing zeitgeist about the dangers of mothers sleeping with their infants and how barbershops may offer a teaching opportunity regarding heart disease, among other topics.
Concerns Rise As Sutter Hospitals Provide Few Details Following Crash Of Information System
While Sutter Health executive officer Sarah Krevans says everyone was provided “high-quality, safe patient care,” during the outage, patients, doctors and nurses describe a different picture.
